Navigation Links
Prostate cancer signal reawakens 'sleeper agent' cells in bones

Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.

Metastasis is the spread of cancer from one organ to another and is a highly complex process, involving cancer cells breaking away from a primary tumour, travelling to a distant organ and colonising it. Cancer cells that fail to form a tumour in the newly-encountered tissue can fall into a dormant state.

Researchers from the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute in California found that dormant prostate cancer cells within bone tissue can be reawakened to a cancerous state when exposed to RANKL, a molecule commonly produced in inflammatory cells. This reawakening can lead to metastatic prostate cancer in bone tissue.

Produced by prostate cancer cells, RANKL is a signalling molecule that has been previously linked with human prostate cancer survival. In this study, researchers engineered a clinically relevant prostate cancer cell line to overproduce RANKL. They found that these cells could significantly alter the gene expression of surrounding cells in vitro, causing them to transform into aggressive cancer cells.

Researchers then injected engineered RANKL cells directly into the blood circulation of mice, which caused dormant cells within the skeleton to re-awaken, ultimately creating tumours within the bone. When the RANKL receptor was blocked, these tumours did not form.

After examination, these tumours were found to contain both the RANKL-overproducing prostate cancer cells, as well as the dormant cells, which had been transformed to become cancerous. Remarkably, the transformed cells displayed aggressive traits that would make them resistant to the normal hormone therapies used to treat prostate cancer.

The findings are preliminary as the study used prostate cancer cells that had been engineered to overproduce RANKL. The next step is to see if other cells known to produce RANKL may also be able to recruit dormant cells to colonise bone tissue.

"We are currently embarking into clinical research with human patients," said lead researcher and postdoctoral fellow Chia-Yi (Gina) Chu, PhD. "Though more work must be done to understand how RANKL reprograms dormant cells to become cancerous, we look forward to examining its influence on promoting metastasis and secondary tumours."

Each year, a quarter of a million men die from prostate cancer worldwide (1). Bones are the most common site of prostate cancer metastases and are typically lethal in 72 percent of cases based on a five year survival rate (2). "If we can prevent prostate cancer metastasis to bone we would significantly enhance patient quality of life and increase survival rates," added Chu.


Contact: Omar Jamshed
BioScientifica Limited

Related medicine news :

1. Scientists develop powerful new animal model for metastatic prostate cancer
2. Researchers identify possible explanation for link between exercise & improved prostate cancer outcomes
3. Melatonin may lower prostate cancer risk
4. Researchers develop tool to determine individual risk of prostate cancer overdiagnosis
5. Increased risk of prostate cancer in African-American men; implications for PSA screening
6. Cleveland Clinic receives grant to study role of DNA damage in treatment-resistant prostate cancer
7. Prosvent Emerges As Preferred Treatment For Enlarged Prostate
8. Pain drugs used in prostate gland removal linked to cancer outcome, Mayo Clinic-led study finds
9. Better guidelines, coordination needed for prostate cancer specialists
10. New Treatment Now Available That Extends Life in Men with Highly Advanced Prostate Cancer
11. Inflammation in prostate may reduce cancer risk
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), ... population health arenas, is pleased to announce that VIP Care Services, a Caprock ... implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case management ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... addition of the "Veterinary Equipment and Disposables ... to 2020" report to their offering. ... of the "Veterinary Equipment and Disposables Market ... 2020" report to their offering. --> ...
(Date:12/1/2015)... , Dec. 1, 2015   MabVax Therapeutics Holdings, ... company, announces it has filed an Investigational New Drug ... (FDA) for the Company,s lead fully human antibody product ... acceptance, MabVax plans to initiate the Phase I clinical ... --> The planned Phase I trial ...
Breaking Medicine Technology: